Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer.

Abstract

OBJECTIVES Trastuzumab, an antic-erbB-2 monoclonal antibody, has become a standard component of chemotherapy for c-erbB-2-positive advanced breast carcinoma. Despite the experimental evidence of its radiosensitizing properties, trastuzumab has never been used in combination with radiotherapy for the treatment of patients with locally advanced disease… (More)

Topics

Cite this paper

@article{Koukourakis2005HypofractionatedAR, title={Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer.}, author={Michael I. Koukourakis and John Manavis and Costantinos Simopoulos and Vasilis Liberis and Alexandra N Giatromanolaki and Efthimios L Sivridis}, journal={American journal of clinical oncology}, year={2005}, volume={28 5}, pages={495-500} }